Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 14, 2019 02:30 ET | Source: Active Biotech

Active Biotech Delårsrapport januari – september 2019

Väsentliga händelser under kvartal 3 Framtagande av en ny affärsplan för laquinimod och tasquinimod, baserad på de omfattande tidigare framtagna prekliniska och kliniska data, pågårData från...
November 14, 2019 02:30 ET | Source: Active Biotech

Active Biotech Interim report January – September 2019

Third quarter in brief A new business plan for laquinimod and...
November 05, 2019 05:00 ET | Source: Active Biotech

Nya prekliniska data för naptumomab estafenatox kommer att presenteras vid Society for Immunotherapy of Cancer’s 34th Annual Meeting

Lund Sverige, 5 november, 2019 - Active Biotech (NASDAQ STOCKHOLM: ACTI) meddelar att deras partner NeoTX kommer att presentera nya prekliniska data för läkemedelskandidaten naptumomab estafenatox...
November 05, 2019 05:00 ET | Source: Active Biotech

New preclinical data on naptumomab estafenatox will be presented at the Society for Immunotherapy of Cancer’s 34th Annual Meeting

Lund Sweden, November 5, 2019 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announces that its partner NeoTX will present new preclinical data on the drug candidate naptumomab estafenatox (naptumomab,...
October 28, 2019 03:30 ET | Source: Active Biotech

Active Biotech och NeoTX meddelar idag att den första patienten har doserats i fas 1b-studien av naptumomab estafenatox i kombination med durvalumab i solida tumörer

Lund Sverige, 28 oktober, 2019 - Active Biotech (NASDAQ STOCKHOLM: ACTI) och NeoTX tillkännager att den första patienten doserats i deras fas 1b-studie av naptumomab estafenatox (naptumomab, ANYARA)...
October 28, 2019 03:30 ET | Source: Active Biotech

Active Biotech and NeoTX today announce first patient dosed in the Phase 1b trial of naptumomab estafenatox in combination with durvalumab in solid tumors

Lund Sweden, October 28 2019 - Active Biotech (NASDAQ STOCKHOLM: ACTI) and NeoTX announce that the dosing of the first patient in its Phase 1b trial of naptumomab estafenatox (naptumomab, ANYARA) in...
September 23, 2019 02:30 ET | Source: Active Biotech

Active Biotech: Nya data från fas 2-studien LEGATO-HD med laquinimod i Huntingtons sjukdom presenteras på den internationella kongressen ”Parkinson’s disease and movement disorders”

Lund den 23 september, 2019 - Active Biotech (NASDAQ STOCKHOLM: ACTI) meddelar att nya data från fas 2-studien LEGATO-HD med laquinimod i Huntingtons sjukdom kommer att presenteras i Nice,...
September 23, 2019 02:30 ET | Source: Active Biotech

Active Biotech: New data on laquinimod from the Phase 2 LEGATO-HD study in Huntington’s disease will be presented at the International congress of Parkinson’s disease and movement disorders

Lund Sweden, September 23, 2019 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announces that new data from exploratory analysis of the Phase 2 LEGATO-HD study of laquinimod in Huntington’s disease...
August 08, 2019 02:30 ET | Source: Active Biotech

Active Biotech AB: Delårsrapport januari – juni 2019

Väsentliga händelser under kvartal 2 Extra bolagsstämma den 4 april 2019, beslöt i enlighet med styrelsens förslag, om godkännande av överlåtelse av bolagets fastighet, till Estea...
August 08, 2019 02:30 ET | Source: Active Biotech

Active Biotech AB: Interim report January – June 2019

Significant events during the second quarter In accordance with the Board’s proposal, the Extraordinary General Meeting on April 4, 2019, resolved to approve the sale of the company’s...